Found 10 clinical trials
Assessment of Drug-drug Interactions Between Masculinizing Hormone Therapy and Antiretroviral Agents Concomitantly for Pre-exposure Prophylaxis Among Transgender Men
There are currently no published studies addressing drug-drug interactions (DDI) between masculinizing hormone therapy (MHT) and pre-exposure prophylaxis (PrEP) among transgender men (TGM). This could lead to concerns and subsequent prioritizing MHT over PrEP among TGM. Because tenofovir alafenamide (TAF) can achieve higher intracellular tenofovir diphosphate (TFV-DP) levels with lower …
- 0 views
- 26 Jan, 2021
- 1 location
Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs
This is a single-center, open label study to identify adherence levels of commonly prescribed FDA-approved antiretroviral agents by tracking the decline of drug concentrations in plasma, urine
- 0 views
- 25 Jan, 2021
- 1 location
Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'
" to start ART against pragmatic and practical safe initiation of treatment needs to be tested using currently available safe potent antiretroviral agents in a head-to-head comparison study to allow
- 0 views
- 18 Jun, 2021
- 3 locations
Catalysing the Containment of COVID-19
profile. No clinically significant interactions are expected with commonly used antihypertensive agents, anti-diabetics drugs, antiretroviral agents, steroids or commonly prescribed analgesics/anti
- 42 views
- 14 Jun, 2021
- 4 locations
7-valent Pneumococcal Conjugated Vaccination
Hypothesis: the efficacy of 2 doses 7-valent PCV is equivalent to 1 dose 7-valent PCV.
- 0 views
- 07 Nov, 2020
The Detection of Drug-Resistant HIV-1 in Taiwan
To assess the HIV resistance rate to variable antiretroviral agents in Taiwan, especially in patients with treatment failure, and to know the correlation between the drug resistance
- 3 views
- 07 Nov, 2020
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.
Due to the potential for pregnancy-induced changes in the pharmacokinetics of medication, one cannot assume that the currently licensed doses of the medication to be tested under this protocol lead to adequate exposure in an HIV-infected pregnant woman. For the agents under study no or limited pharmacokinetic data during pregnancy …
- 156 views
- 25 Mar, 2021
- 25 locations
Risk of Morbidity Mortality and Long-term Monitoring of Antiretroviral Treatment in People Living With HIV
HIV infection is now a chronic disease in countries where antiretroviral treatments (ART) are largely available. Long-term follow-up is required to describe and understand the evolution of morbidities and complications as well as new treatments side effects. The main objective of the cohort is to describe and study the evolution …
- 2 views
- 08 Mar, 2021
- 40 locations
A Long-term Follow-up of the HIV-NAT Cohort
With HIV/AIDS increasingly considered a chronic disease, 24-, or 48-week data from antiretroviral studies are no longer sufficient. Only with long-term follow-up and outcome data will shed some much-needed light on the answers of questions that have stumped us for several years. Data from a large observational cohort of patients …
- 2 views
- 25 Jan, 2021
- 1 location
REal-Life Cohort With DOlutegravir + LAmivudina
antiretroviral therapy (ART). Two-drug regimens (2DRs) have been investigated as a means for reducing the number of antiretroviral agents (ARVs) taken by individuals who need lifelong ART. Dovato (Dolutegravir
- 0 views
- 14 Apr, 2021
- 1 location